tbuckley/cabot-search huggingface dataset:
Methadone as the initial long-acting opioid in children with advanced cancer.
Authors: Kevin Madden, Sarah Mills, Seyedeh Dibaj, Janet L. Williams, Diane D Liu, Eduardo Bruera
Journal: Journal of Clinical Oncology (2017)

224 Background: Methadone is an attractive medication for treating children with advanced cancer who have chronic pain, as it is the only long-acting opioid available as a liquid. This formulation allows for precise dosing that is not possible with the fixed dose of extended release tablets or transdermal patches. Additionally, it can be used in children unable to reliably swallow tablets. Many pediatric oncologists are concerned with methadone’s complex pharmacodynamics and pharmacokinetics, and so it is often relegated to being the long-acting opioid to use only after long-acting morphine, long-acting oxycodone, and fentanyl transdermal patches have proven to be ineffective in controlling pain. We believe that methadone has a role as the first long-acting opioid in children who have uncontrolled pain while only on immediate-release mu opioid agonists. Methods: Retrospective chart review of 52 consecutive patients referred to Pediatric Supportive Care for pain management started on methadone as their first long-acting opioid. Data collected at baseline and first follow up visit (F1) included child- and parent-reported outcomes for various physical and psychological symptoms, opioid side effects and other clinical data. All symptoms were rated on a 5 point scale: 0 (not at all), 1 (a little bit), 2 (kind of), 3 (quite a bit) and 4 (a lot). Results: Of 52 eligible patients, a majority (47, 90.3%) were assessed at F1. Reasons for not evaluating patients at F1 included death (3) (none died of cardiac arrhythmia or opioid related toxicity) and transfer of care to another facility (2). Pain as scored by the child was 3.6/4 at baseline and 1.8/4 at F1 (P &lt; 0.0001). Pain as scored by the parent was 3.5/4 at baseline and 1.4 at F1 (P &lt; 0.0001). A majority of patients (33, 70.2%) at F1 did not need a change in their methadone dose. A small number (10, 21.3%) needed an increase in their methadone dose due to inadequate pain control; a few (4, 8.5%) had a lower methadone dose but all were part of tapering methadone due to resolution of the original pain syndrome, not due to opioid toxicity. Conclusions: Initiation of methadone was effective and safe as the first long-acting opioid in children with pain due to advanced cancer.
Gamma knife radiosurgery for treatment of cavernous sinus meningioma patients in Tangerang, Indonesia: A preliminary study
Authors: P. Wibisono, A.D. Vatvani, S.M. Evangelina, A.G. Widjaja, E. Soediatmoko, I. Hasbiullah, L. Hendriansyah
Journal: Annals of Oncology (2017)
The effect of tissue ischemia on gene expression in prostate tissue
Authors: Andreas M. Luebke, Esther Näkel, Holger Sültmann, Hartwig Huland, Kerstin A. David, Olaf J C Hellwinkel, Thorsten Schlomm
Journal: Cancer Research (2006)

855   Aims: The significance of RNA based techniques like cDNA microarray and RT-PCR gene expression analysis highly depends on the quality of the processed tissue. Tissue ischemia changes the cellular transcriptional profile, and RNA is very susceptible to degradation by RNAses. We analyzed the influence of ischemia time on the gene expression profile of malignant and non-malignant prostate tissue. Methods: Tissue specimens from 10 patients were taken by needle core biopsies preoperatively (native tissue), every 10 minutes during prostatectomy (warm ischemia) and every 10 minutes (0 to 180 minutes) after extirpation of the prostate (cold ischemia), and were immediately stored in RNAlater. For whole genome analyses total RNA was isolated and amplified by T7-based RNA-polymerase in vitro transcription. Gene expression profiling was performed by cDNA-Microarrays (Human Unigene Set RZPD3.1), as well as TaqMan qRT-PCR from 96 prostate cancer associated genes. Results: By cDNA microarrays, we could identify genes with ischemia-associated differential expression, which partially have not been described to be linked with anoxic stress response so far; among them DUSP1, KLK2 and STAG3. Further analysis by RT-PCR revealed differentially expression in around 10% of 96 prostate cancer associated genes; among them PIM1, p21, Krt17 and c-myc. Some (e.g. EGR1) reacted to ischemic stress in a very early state. Conclusions: Ischemia has a strong influence on gene expression. Although many prostate cancer associated genes seem to be stable for a long time, hypoxic stress needs to be addressed to design adequate tissue extraction and processing strategies, allowing artifact-free, accurate and specific gene expression studies.
P2.02-005 A Rare Clinical Presentation Of EGFR-Mutant Non-Small Cell Lung Cancer With Oligo-Acrometastasis
Authors: Pınar Akın Kabalak, Tuba Inal Cengiz, Ugur Yılmaz, Derya Kızılgöz, Metehan Karaca, Fatma Canbay, Inci Uslu, Yetkin Ağaçkıran, Kyle Wang
Journal: Journal of Thoracic Oncology (2017)
Abstract 17733: Impact of Stent Deformation Induced by Kissing Balloon Technique for Coronary Bifurcation Lesions on Clinical Outcomes
Authors: Tadatsugu Gamou, Youhei Yakuta, Chikara Fujita, Daisuke Tsujimoto, Ryusuke Kimura, Hidenobu Terai, Yuki Horita, Masatoshi Ikeda, Masanobu Namura
Journal: Circulation (2016)

Background:  Final kissing balloon technique (KBT) for coronary bifurcation lesions induces proximal stent deformation. The aim of this study was to investigate the impact of second-generation drug-eluting stent deformation evaluating by intravascular ultrasound imaging on clinical outcomes.   Methods:  From February 2010 to April 2015, 377 consecutive bifurcation lesions treated with second-generation drug-eluting stents were divided into two groups according to KBT, KBT group (n = 176) and no-KBT group (n = 201). Based on intravascular ultrasound analysis, the stent symmetry index (minimum / maximum stent diameter) and the stent overstretch index (the mean of minimum and maximum stent diameter / the mean of minimum and maximum reference diameter) were calculated.   Results:  ACC/AHA type B2/C lesion was significantly greater in the KBT group compared with the no-KBT group (84% vs. 68%; p = 0.0004). The stent symmetry index was significantly lower (0.75 ± 0.07 vs. 0.87 ± 0.06; p    Conclusion:  Stent deformation induced by KBT for complex bifurcation lesions was not associated with adverse mid-term outcomes.
Abstract 14623: ICAM-1 Mediates Hyperhomocysteinemia Accelerated Arteriolar Thrombosis and Endothelial -Platelets Interaction
Authors: Shu Meng, Soochong Kim, Xiaohua Jiang, Zhongjian Cheng, Satya P Kunapuli, Rolando Rumbaut, Xiaofeng Yang, Hong Wang
Journal: Circulation (2012)

Background:  Hyperhomocysteinemia (HHcy) is an established risk factor for atherothrombogenic diseases. In this study we investigated the effect of HHcy on EC-platelets interaction and its role in thrombosis.    Methods and Results:  We used a novel mouse model of HHcy (plasma homocysteine, Hcy 80 μ M) in which a Zn 2+  inducible human  cystathionine   β  -synthase  ( C  BS ) transgene was introduced to circumvent the neonatal lethality of  Cbs  deficiency ( Tg-hCBS Cbs −/−    mice). Hcy-lowering therapy was performed by giving ZnSO 4  water to induce human  CBS  transgene expression in adult mice. Thrombus formation was examined by photo-dye induced cremaster microvasculature thrombosis using intra-vital microscope, which preserved the endothelium, and by FeCl 3 -induced carotid artery thrombosis, which denudated the endothelium. HHcy accelerated cremaster arteriolar thrombosis and decreased blood flow cessation time from 41.8 min in control mice to 30.5 min in  Tg-hCBS Cbs   −/−   mice. Venular blood flow cessation time was slightly decreased from 5.6 to 5.0 min. Hcy-lowering therapy reduced Hcy level from 80 μ M to 2 μ M after 2 weeks of ZnSO 4  water and prolonged arteriolar blood cessation time from 30.5 to 37.8 min. Interestingly, FeCl 3 -induced carotid artery thrombosis did not change. Hcy did not potentiate aggregation and secretion of washed human platelets from healthy donor treated with Hcy (50, 100 μ M) and from  Tg-hCBS Cbs −/−    mice. However, ICAM-1 levels, but not VCAM-1, were increased in cremaster tissues from  Tg-hCBS Cbs   −/−   mice by western blot. In cultured human umbilical vein ECs (HUVEC), Hcy (100 μ M, 24h) promoted human platelet adhesion by 200% in static adhesion assay. Using western blot, FACS and RT-PCR, we found that Hcy increased protein and mRNA levels of ICAM-1, but not that of VCAM-1, in HUVEC. ICAM-1 blocking antibody partially reversed Hcy-increased platelets adhesion to HUVEC. Finally, Hcy induced ICAM-1 expression and reduced DNA methylation on ICAM-1 promoter, which were mimicked by DNA methyltransferase inhibitor azacytidine, and histone deacetylase inhibitors sodium butyrate and trichostatin A.    Conclusion:  HHcy accelerates arteriolar thrombosis and increases EC-platelets interaction via ICAM-1 induction partially through promoter hypomethylation.
Will human-like machines make human-like mistakes?
Authors: Evan J Livesey, Micah B Goldwater, Ben Colagiuri
Journal: Behavioral and Brain Sciences (2017)

Abstract Although we agree with Lake et al.'s central argument, there are numerous flaws in the way people use causal models. Our models are often incorrect, resistant to correction, and applied inappropriately to new situations. These deficiencies are pervasive and have real-world consequences. Developers of machines with similar capacities should proceed with caution.
Analysis of retreatment after radiotherapy for bone metastasis at a safety net hospital.
Authors: Richard Lester Stephen Jennelle, Jacob Andrade, Patrick Williams, Shelly Bian, Omar Medhat Ragab, Stella Yoo, Anthony Pham, Peter Lai, Naomi Schechter, Leslie K. Ballas, Eric L. Chang
Journal: Journal of Clinical Oncology (2017)

223 Background: The effectiveness of single fraction radiotherapy in the treatment of bone metastasis is firmly established by multiple prospective randomized controlled trials. These trials have also indicated a retreatment rate that is significantly higher for patients treated with single fraction radiotherapy. The reason for this is unclear. The prior studies have confirmed that there are no differences in any objective or subjective measure of response or durability of response. One proposed explanation may be a conscious or subconscious impact of practice based workload accounting for adopting a single fraction treatment strategy that may lead to excess retreatment prescription. In other words, does a decrease in workload accounting due to single fraction treatment lead to an increase in retreatment rates? Our large safety net teaching hospital follows a practice model where department funding is independent of workload accounting. We retrospectively reviewed our data on the radiotherapy of bone metastasis to see if this practice model had any impact on our retreatment rates. Methods: Between October 2012 and June 2017, 225 patients received treatment for 385 target lesions. All referred patients’ entire radiotherapy history was included whether or not it occurred during the target period. 196 target lesions received single fraction treatment and 189 received multiple fractions. 27 target lesions were retreated once and a single target lesion was retreated twice. Results: Target lesions treated with a single fraction resulted in a retreatment rate of 7.7% while multiple fraction treatment resulted in a retreatment rate of 6.4%. This difference was not statistically significant by Chi-Square analysis. Conclusions: Our retrospective analysis confirms no difference in retreatment rates between single and multi-fraction treatment. The retreatment rate is in agreement with the published response rate and introduces a possible explanation for the discordant rates observed in the published literature. Further analysis involving multiple practice models would help further explore these findings.
A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations
Authors: Takeshi Yamaura, Toshiyuki Nakatani, Ken Uda, Hayato Ogura, Wigyon Shin, Naoya Kurokawa, Koichi Saito, Norie Fujikawa, Tomomi Date, Masaru Takasaki, Daisuke Terada, Atsushi Hirai, Akimi Akashi, Fangli Chen, Yoshiya Adachi, Yuichi Ishikawa, Fumihiko Hayakawa, Shinji Hagiwara, Tomoki Naoe, Hitoshi Kiyoi
Journal: Blood (2017)
Functional heparin-PF4 antibodies from patients with heparin-induced thrombocytopenia cause platelet-monocyte aggregation Implications for the pathogenesis of HIT
Authors: S. Ahmad, A. Amirkhosravi, J. M. Walker, R. Dorfman, M. Amaya, H. Desai, T. Meyer, J. L. Francis
Journal: Blood (2003)
Optimizing dosing in navigation interventions across the cancer continuum: A planned secondary data analysis from the Patient Care Connect implementation.
Authors: Elizabeth Ann Kvale, Maria J Pisu, Courtney Williams, Kelly Kenzik, Andres Azuero, Pradeep Sharma, Karina I. Halilova, Rodney Paul Rocconi, Guilherme Henrique Cantuaria, Edward E. Partridge, Gabrielle Betty Rocque
Journal: Journal of Clinical Oncology (2017)

174 Background: Patient navigation programs in cancer care have historically focused on assisting persons to overcome barriers to accessing care. Evidence is emerging to support the impact of navigation interventions across the cancer continuum. However, navigation programs have varied designs, resulting in a lack of clarity about the optimal approach to delivering services to patients, and a lack of evidence linking program design to outcomes. Methods: A planned retrospective analysis of Medicare administrative claims for a population of older beneficiaries diagnosed with cancer: The main exposure was the number of contacts in person or over the phone with PCCP navigators in the 6 month period starting from the quarter in which patients enrolled in the PCCP. Repeated measures generalized linear models with normal distribution were used to evaluate trends in total cost over time based on: number of contacts, quarters post-enrollment (TIME), and the interaction between number of contacts and TIME. Intra-correlation was controlled for repeated measures. Results: 4,337 patients were included in this analysis. 17.9% had one contact, 17.7% had two, 22.2% had 3-4, 24.2% had 5-10, and 18.0% had more than 10 contacts. African Americans had a greater number of participants with more than 10 navigator contacts, as stage 4 cancers, and initial or end-of-life phase of care. Patients who received more than 3 contacts had significantly higher levels of baseline cost. Models to evaluate total cost over time demonstrate an effect of navigator contact on cost that is associated with number of contacts. This trend is statistically significant at 3-4 contacts or more, and remains significant at 10 or more contacts. Conclusions: Increased navigator contact is associated with increased slope of decline in utilization and cost indicates that navigation programs should be adequately resourced to deliver care that enables navigators to have contact with patients a minimum of 3-4 contacts over a six month period.
A Potential Role for Adjuvant Chemotherapy and Radiotherapy for Patients With High-Risk Bladder Cancer Treated With Cystectomy in the United States
Authors: Dayssy A. Diaz, Amir Mortazavi, Cheryl T. Lee
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Allergen Concerns and Popular Skin Care Products—Reply
Authors: Shuai Xu, Michael Kwa, Jonathan I. Silverberg
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial
Authors: L. Buisseret, S. Pommey, B. Allard, S. Garaud, M. Bergeron, I. Cousineau, L. Ameye, Y. Bareche, M. Paesmans, J.P.A. Crown, A. Di Leo, S. Loi, M. Piccart-Gebhart, K. Willard-Gallo, C. Sotiriou, J. Stagg
Journal: Annals of Oncology (2017)
Genome-Based Treatment Algorithm to Prevent Relapse in Children and Young Adults with Acute Lymphoblastic Leukemia: A Prospective Feasibility Study
Authors: Jodi Mayfield, David Czuchlewski, James Gale, Ksenia Matlawska-Wasowska, Mohammad Vasef, Christian K Nickl, Cecilia Arana Yi, Gavin Pickett, Scott Ness, Stuart S. Winter
Journal: Blood (2016)
Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States
Authors: Anil K. Chaturvedi, Barry I. Graubard, Tatevik Broutian, Robert K.L. Pickard, Zhen-Yue Tong, Weihong Xiao, Lisa Kahle, Maura L. Gillison
Journal: Journal of Clinical Oncology (2017)

Purpose The incidence of human papilloma virus (HPV)-positive oropharyngeal cancers has risen rapidly in recent decades among men in the United States. We investigated the US population-level effect of prophylactic HPV vaccination on the burden of oral HPV infection, the principal cause of HPV-positive oropharyngeal cancers. Methods We conducted a cross-sectional study of men and women 18 to 33 years of age (N = 2,627) within the National Health and Nutrition Examination Survey 2011 to 2014, a representative sample of the US population. Oral HPV infection with vaccine types 16, 18, 6, or 11 was compared by HPV vaccination status, as measured by self-reported receipt of at least one dose of the HPV vaccine. Analyses accounted for the complex sampling design and were adjusted for age, sex, and race. Statistical significance was assessed using a quasi-score test. Results Between 2011 and 2014, 18.3% of the US population 18 to 33 years of age reported receipt of at least one dose of the HPV vaccine before the age of 26 years (29.2% in women and 6.9% in men; P < .001). The prevalence of oral HPV16/18/6/11 infections was significantly reduced in vaccinated versus unvaccinated individuals (0.11% v 1.61%; Padj = .008), corresponding to an estimated 88.2% (95% CI, 5.7% to 98.5%) reduction in prevalence after model adjustment for age, sex, and race. Notably, the prevalence of oral HPV16/18/6/11 infections was significantly reduced in vaccinated versus unvaccinated men (0.0% v 2.13%; Padj = .007). Accounting for vaccine uptake, the population-level effect of HPV vaccination on the burden of oral HPV16/18/6/11 infections was 17.0% overall, 25.0% in women, and 6.9% in men. Conclusion HPV vaccination was associated with reduction in vaccine-type oral HPV prevalence among young US adults. However, because of low vaccine uptake, the population-level effect was modest overall and particularly low in men.
Hindsight and moving the needle forwards on rehabilitation trial design
Authors: Bronwen Connolly, Linda Denehy
Journal: Thorax (2017)

> Hindsight: the ability to understand, after something has happened, what should have been done or what caused the event.1 

The first randomised controlled trials (RCTs) of physical rehabilitation in critically ill patients in the intensive care unit (ICU) were published nearly 10 years ago demonstrating favourable results and heralding a groundswell of clinical and research activity in the field.2 3 Ensuing RCTs continued to investigate the peri-ICU period4 5 but additionally mapped the rehabilitation pathway to include post-ICU discharge on the ward6 and community7 8 and across the continuum of care.9 However, this impressive body of literature has challenged a transformation in clinical practice. Recent studies have failed to show a difference in primary outcome,4 5 but is this truly failure of interventions to demonstrate effect or failure of intervention delivery within an appropriately designed study? Hindsight is a valuable perspective to interpret this premise. Triallists need to pre-empt advances in knowledge and understanding of the topic in order to future-proof their research. It is easy to lament what could have been done differently. Acknowledging this, these trials have contributed greatly to our current understanding of the intricacies of design, conduct and evaluation of trials of complex rehabilitation interventions in critical care.

Against this backdrop, Wright and colleagues present their Intensive versus standard physical rehabilitation therapy in the critically ill (EPICC) study, a multicentre RCT investigating intensive versus standard physical rehabilitation therapy in the ICU.10 This is the first UK trial of its kind, recruiting 308 participants to receive either intervention (target 90 min per day) or control (target 30 min per day) physical rehabilitation treatment. The primary outcome was health-related quality of life measured using the Physical Component Summary (PCS) of the Short-Form-36 (SF-36) at 6 months. Intention-to-treat analysis revealed no difference between groups, mean …
Higher altitude, bigger bulla
Authors: Xian-Ning Wu, Dan Su, Xiao-Feng Zhu, Mei-Qing Xu
Journal: Thorax (2017)

A 28-year-old woman presented to the emergency centre of First People’s Hospital of Yunnan Province with a 10-day history of dyspnoea and chest tightness. She had no history of cigarette smoking or drug use and no personal or family history of respiratory diseases. She used to live in Hefei, Anhui Province (with an average altitude of 20 metres). Ten days prior to presentation, she had moved to Kunming, Yunnan Province (a higher altitude area with an average altitude of 1900 metres) to take up a new job. She was in mild distress with an oxygen saturation of 95% while breathing ambient air. The physical examination revealed hyper-resonance and decreased breath sounds in the right hemithorax. The chest X-ray demonstrated a large lucency occupying the entire right hemithorax, with contralateral mediastinal shift (figure 1A). Subsequently, CT of chest revealed no sign of compressed lung tissue on the right (figure 1B …